Paradigm Biocapital Advisors LP Edgewise Therapeutics, Inc. Transaction History
Paradigm Biocapital Advisors LP
- $2.77 Billion
- Q3 2024
A detailed history of Paradigm Biocapital Advisors LP transactions in Edgewise Therapeutics, Inc. stock. As of the latest transaction made, Paradigm Biocapital Advisors LP holds 2,789,172 shares of EWTX stock, worth $85.9 Million. This represents 2.68% of its overall portfolio holdings.
Number of Shares
2,789,172
Previous 2,325,449
19.94%
Holding current value
$85.9 Million
Previous $41.9 Million
77.75%
% of portfolio
2.68%
Previous 1.69%
Shares
3 transactions
Others Institutions Holding EWTX
# of Institutions
191Shares Held
100MCall Options Held
2.17MPut Options Held
410K-
Orbimed Advisors LLC San Diego, CA15MShares$462 Million9.45% of portfolio
-
Ra Capital Management, L.P. Boston, MA8.91MShares$274 Million3.32% of portfolio
-
Black Rock Inc. New York, NY6.02MShares$185 Million0.0% of portfolio
-
Baker Bros. Advisors LP New York, NY5.84MShares$180 Million1.67% of portfolio
-
Novo Holdings Hellerup, G75.55MShares$171 Million10.36% of portfolio
About Edgewise Therapeutics, Inc.
- Ticker EWTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 63,171,700
- Market Cap $1.94B
- Description
- Edgewise Therapeutics, Inc., a biopharmaceutical company, develops small molecule therapies for musculoskeletal diseases. The Company's lead product candidate, EDG-5506, is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy which has c...